These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Two new drugs for homozygous familial hyperchelesterolemia. Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581 [No Abstract] [Full Text] [Related]
6. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880 [TBL] [Abstract][Full Text] [Related]
7. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]
8. Lomitapide for the management of homozygous familial hypercholesterolemia. deGoma EM Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128 [TBL] [Abstract][Full Text] [Related]
9. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Davis KA; Miyares MA Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757 [TBL] [Abstract][Full Text] [Related]
10. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461 [TBL] [Abstract][Full Text] [Related]
11. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
12. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Perry CM Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215 [TBL] [Abstract][Full Text] [Related]
13. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368 [TBL] [Abstract][Full Text] [Related]
14. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Stefanutti C Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261 [TBL] [Abstract][Full Text] [Related]
15. Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol. Das G; Rees A Curr Opin Lipidol; 2014 Dec; 25(6):471-3. PubMed ID: 25370457 [No Abstract] [Full Text] [Related]
16. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Chacra APM; Ferrari MC; Rocha VZ; Santos RD J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303 [TBL] [Abstract][Full Text] [Related]
17. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Cuchel M; Blom DJ; Averna MR Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075 [TBL] [Abstract][Full Text] [Related]